Fisher Asset Management LLC trimmed its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.5% in Q1, according to its latest 13F filing with the Securities and Exchange Commission. The institutional investor held 638,232 shares of the company after selling 9,777 shares during the quarter. Fisher Asset Management LLC’s holdings in Johnson & Johnson were worth $113,114,000 at the end of the last quarter.
Several other hedge funds and other institutional investors have also recently added or reduced their stakes in JNJ. Family CFO Inc purchased a new stake in Johnson & Johnson in Q4 worth approximately $26,000. Steward Financial Group LLC bought a new position in Johnson & Johnson in Q4 worth around $34,000. Professional Financial Advisors LLC increased its stake in Johnson & Johnson by 47.9% in the 1st quarter. Professional Financial Advisors LLC now owns 210 shares of the company worth $37,000 after purchasing an additional 68 shares during the period. Joseph P. Lucia & Associates LLC bought a new position in Johnson & Johnson in Q1 worth approximately $38,000. Finally, Advocacy Wealth Management Services LLC increased its stake in Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company worth $41,000 after purchasing an additional 67 shares during the period. 68.78% of the shares are held by hedge funds and other institutional investors.
Wall Street analysts predict growth
Several research companies have weighed in on JNJ. Citigroup lowered its price target on Johnson & Johnson from $205.00 to $201.00 in a Wednesday July 20 research note. Goldman Sachs Group raised its price target on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a Tuesday, April 12 research note. Daiwa Capital Markets began covering Johnson & Johnson in a research note on Wednesday June 22. They gave the company an “outperform” rating. SVB Leerink lowered its target price on Johnson & Johnson from $200.00 to $194.00 in a Wednesday July 20 research report. Finally, StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong buy” rating in a Tuesday, May 17 research report. Four equity research analysts gave the stock a hold rating, five gave the company a buy rating and one gave the company a strong buy rating. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $189.89.
Johnson & Johnson shares down 0.5%
Shares of JNJ opened at $170.20 on Tuesday. The company has a market capitalization of $447.49 billion, a PE ratio of 24.77, a P/E/G ratio of 3.25 and a beta of 0.59. The company has a fifty-day moving average of $175.00 and a 200-day moving average of $174.71. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt ratio of 0.37.
Johnson & Johnson Inc (NYSE:JNJ – Get Rating) last released its quarterly results on Tuesday, July 19. The company reported earnings per share (EPS) of $2.59 for the quarter, beating analyst consensus estimates of $2.57 by $0.02. The company posted revenue of $24.02 billion in the quarter, versus a consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. Johnson & Johnson revenue increased 3.0% year-over-year. During the same period last year, the company earned earnings per share of $2.48. On average, sell-side analysts expect Johnson & Johnson to post 10.05 EPS for the current year.
Johnson & Johnson Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 6. Shareholders of record on Tuesday, August 23 will receive a dividend of $1.13. The ex-dividend date is Monday, August 22. This represents a dividend of $4.52 on an annualized basis and a yield of 2.66%. Johnson & Johnson’s payout ratio is 65.79%.
Insiders place their bets
In other Johnson & Johnson news, Executive Vice President Kathryn E. Wengel sold 40,000 shares in a trade on Friday, June 10. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares of the company, valued at $12,336,803. The transaction was disclosed in a legal filing with the SEC, accessible via the SEC’s website. In other news, CAO Robert J. Decker sold 8,462 shares of the company in a trade Thursday, May 26. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company, valued at $2,785,140. The sale was disclosed in a legal filing with the SEC, accessible via this link. Additionally, Executive Vice President Kathryn E. Wengel sold 40,000 shares of the company in a trade on Friday, June 10. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. As a result of the transaction, the executive vice president now owns 71,311 shares of the company, valued at approximately $12,336,803. The disclosure of this sale can be found here. Insiders own 0.35% of the shares of the company.
Johnson & Johnson Company Profile
(Get a rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.
Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.